Loading
Pharmacology and Obesity Treatment / Diabetes Treatment and Management / Regulation of Appetite and Obesity · Journal article
Hormone and Metabolic Research · September 4, 2026
A consensus or society position rather than new primary data.
This is a narrative literature review summarizing the mechanisms, clinical efficacy, and recent developments of GLP-1 receptor and MC4R agonists, including dual and triple agonists, for obesity and type 2 diabetes treatment. It presents no new primary data and does not quantify the strength of evidence for individual agents or interventions; it is an expert synthesis intended to contextualize emerging therapeutic options rather than establish the magnitude of clinical benefit.
Narrative literature review. People with obesity and type 2 diabetes in the context of aging populations..
Semaglutide and liraglutide promote insulin secretion, suppress appetite, and result in effective weight loss and glycemic control, with semaglutide available in injectable and oral forms. Liraglutide reduces cardiovascular risk. Setmelanotide (MC4R agonist) shows efficacy in genetic obesity.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review provides clinicians with a synthesis of mechanism, agent types, and formulation advances to inform treatment selection, but does not quantify clinical outcomes, effect sizes, or comparative efficacy needed for practice decisions. Clinicians should consult trial data and guidelines for strength of evidence and specific indications.
This is a literature review synthesizing evidence on GLP-1 and MC4R agonists for obesity and type 2 diabetes, presenting expert assessment of mechanisms and clinical efficacy rather than reporting original trial data.
As stated by the source record.
This review provides clinicians with a synthesis of mechanism, agent types, and formulation advances to inform treatment selection, but does not quantify clinical outcomes, effect sizes, or comparative efficacy needed for practice decisions. Clinicians should consult trial data and guidelines for strength of evidence and specific indications.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract: The global rise in aging populations has been accompanied by increasing rates of obesity and type 2 diabetes, both of which pose significant public health and economic challenges. This review aims to investigate the pathophysiological link between obesity and diabetes and evaluate emerging therapeutic strategies that involve glucagon-like peptide-1 receptor and melanocortin-4 receptor agonists, including their dual and triple agonist developments. A comprehensive literature review was conducted focusing on the mechanisms of glucagon-like peptide-1 receptor and melanocortin-4 receptor agonists, their clinical efficacy, and the evolution of combination therapies. Emphasis was placed on recent clinical trials and the development of oral agonist formulations to improve patient compliance. Glucagon-like peptide-1 receptor agonists, such as semaglutide and liraglutide, promote insulin secretion, suppress appetite, and result in effective weight loss and glycemic control. Semaglutide is available in both injectable and oral forms, improving accessibility. Liraglutide also reduces cardiovascular risk. Melanocortin-4 receptor agonists act via the central nervous system to reduce appetite and increase energy expenditure, with setmelanotide showing efficacy in genetic obesity. Dual and triple agonists, such as tirzepatide, simultaneously target glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors, leading to enhanced metabolic outcomes. Oral drugs like rybelsus improve long-term adherence. Glucagon-like peptide-1 receptor and melanocortin-4 receptor agonists, particularly when used as dual or triple agents, represent promising therapeutic innovations for obesity and type 2 diabetes. The development of oral formulations further enhances treatment convenience and adherence, paving the way for improved clinical outcomes.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.